Study links DPP-IV medication to heart failure, hospitalization

Share this article:

A study of Merck's diabetes DPP-IV medication Januvia indicates the treatment may be associated with an increased risk of heart failure coupled with hospitalization. Forbes reports that although a related editorial describes the absolute risk of heart failure with the DPP-IV as “if present at all, appears to be small,” the study's researchers write that the finding could be clinically relevant.

This is the second bit of recent concern for the drug class as a whole–the medications have been scrutinized over the last year-and-a-half over concerns that they could cause pancreatitis, an inflammation which is associated with pancreatic cancer. Regulators in the US and Europe released a middle-of-the-road assessment in February in which neither group could say there was a causal relationship between the drugs and pancreatitis and/or pancreatic cancer, but were going to keep an eye on future data.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.